Additional studies showed the anti-tumor effect is dependent on plasmacytoid DCs (pDCs), which stimulate the ability of conventional type 1 DCs (cDC1s) to prime naïve CD8+ T cells (23, 24). The gene discussed is CD8A; the disease is neoplasm.